arrow_back Back to App

Prohibiting Delay of Generic and Biosimilar Drugs: More Affordable Medicines

This act aims to increase the availability of more affordable generic and biosimilar drugs. It prohibits brand-name drug companies from paying generic companies to delay the market entry of their cheaper alternatives. This means citizens can expect lower drug prices and more choices, positively impacting their personal finances and access to healthcare.
Key points
Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
Aims to increase competition and lower drug prices, leading to savings for patients.
The Federal Trade Commission (FTC) gains new powers to prosecute such unfair practices and impose significant penalties.
article Official text account_balance Process page
Placed on Calendar
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1096
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-03-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Preserve Access to Affordable Generics and Biosimilars Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1096.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-24.

What are the main provisions?

Key points include:

  • Prohibits payments to delay the market entry of cheaper generic and biosimilar drugs.
  • Aims to increase competition and lower drug prices, leading to savings for patients.
  • The Federal Trade Commission (FTC) gains new powers to prosecute such unfair practices and impose significant penalties.
What is the specific legal status?

The current status is Placed on Calendar.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Economy Courts and Law